Human iPSC Line (Episomal, HFF)
|Catalog#||Unit||Unit Price (USD)||Actions|
|iPS11||5x105 cells/vial||$1,557.68||Add to Cart|
Footprint-free human iPS11 cell lines generated by episomal plasmids are ideally suited for various research purpose including 1) differentiating various somatic cells or organoid models for phenotypic and target-based compound screening, 2) establishing genetically modified disease model through CRISPR/Cas9 editing, and 3) generating functional cells/tissues as regenerative biology initiatives. iPS11 has several features such as:
- Low passage and long-term viability
- Off the shelf - simple thaw the cells and plate them onto serum-free, feeder-free culture
- Transgene- and Virus-free (episomal)
- Homogeneity– Originated from a single iPSC clone
Footprint-free human iPS (induced pluripotent stem) cell line (Cat# iPS11) was derived from human foreskin fibroblasts (HFFs) by ectopic expression of OCT4, SOX2, KLF4, and L-MYC genes using Alstem episomal plasmids. The cells were derived using morphological selection criteria and without the use of fluorescent marker or drug selection. When cultured under standard human ES cell culture conditions, the morphology of human iPS cells are identical to that of human ES cells. The cells express the pluripotency markers OCT4, SSEA-3, Nanog, and endogenous alkaline phosphatase. High viability, low passage iPS cells have been pre-adapted to serum-free, feeder-free culture conditions.
|Product Name||Human iPSC Line (Episomal, HFF)|
Dry Ice - Overnight Shipping
|Storage and Stability||
Store in vapor phase of liquid nitrogen immediately upon receipt. This product is stable for 12 months when stored as directed.
Human iPS cells (cat. no. iPS11) were grown in mTeSR1 medium. Each lot of human iPS cells is tested for growth and viability following recovery from cryopreservation. In addition, each lot is tested for expression of OCT4 and TRA-1-60, as well as the activity of alkaline phosphatase.
For Research Use Only. Not for use in diagnostic or therapeutic procedures.
HumanGLB1knockout cerebral organoids: A model system for testingAAV9-mediatedGLB1gene therapy for reducing GM1 ganglioside storage inGM1 gangliosidosis Molecular Genetics and Metabolism Reports (2019)
- Clinical Applications of Induced Pluripotent Stem Cells – Stato Attuale Cell Biology and Translational Medicine (2018)
- Cerebral organoids derived from Sandhoff disease-induced pluripotent stem cells exhibit impaired neurodifferentiation The Journal of Lipid Research (2018)
- Generation and post-injury integration of human spinal cord neural stem cells Nature Methods (2018)
- Pseudotyping exosomes for enhanced protein delivery in mammalian cells International Journal of Nanomedicine (2017)
- (Patent) Generation of Human Spinal Cord Neural Stem cells United States Patent Application 20200087623 (2020)
- (Patent) Engineered Exosomes for the Delivery of Bioactive Cargo Using Transmembrane VSV-G United States Patent Application 20190015333A1 (2019)